Organ-specific response after low-dose interleukin-2 therapy for steroid-refractory chronic graft-versus-host disease.

ABSTRACT: Despite new therapeutic options, treatment of steroid-refractory chronic graft-versus-host disease (SR-cGVHD) remains challenging as organ involvement and clinical manifestations are highly variable. In previous trials of low-dose interleukin-2 (LD IL-2), we established the safety and efficacy of LD IL-2 for the treatment of SR-cGVHD. In the present report, we combined five phase 1 or 2 clinical trials conducted at our center to investigate organ-specific response rate, coinvolvement of organs, predictors of organ-specific response, and its possible association with immune response. For the 105 adult patients included in this report, the overall response rate after 8 or 12 weeks of LD IL-2 was 48.6% and 53.3%, including late responses in patients who continued treatment for extended period

SUBMITTER: Kim HT 

PROVIDER: S-EPMC9636330 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature